# Alnylam Pharmaceuticals (ALNY): value investors who own it

2 value investors held Alnylam Pharmaceuticals in their Q3 2026 13F, led by Dodge & Cox, Horizon Kinetics.

## 13F holders

| Manager | Portfolio | Value | Change | Quarters held |
| --- | --- | --- | --- | --- |
| Dodge & Cox | 0.3% | $589m | Added +1.4% | 41 |
| Horizon Kinetics | 0.0% | $653k | Trimmed -4.6% | 25 |

## Directors buying and selling (Form 4, last 12 months)

| Date | Who | Role | Bought or sold | Shares | Value |
| --- | --- | --- | --- | --- | --- |
| 2026-10-02 | SUPRAN BRYAN | EVP, CLO and Secretary | Sold | 1758 | $399k |

## Fund holders

| Fund | Manager | Weight | Value | As at |
| --- | --- | --- | --- | --- |
| Dodge & Cox Global Stock Fund | Dodge & Cox | 0.4% | $48.7m | 2026-06-30 |

Source: SEC filings, via moatshark (https://www.moatshark.com/s/alny). Values traded and returns are estimates. Not investment advice. Built 2026-10-21.